Public Workshop - Device Improvements for Pediatric X-ray Imaging, July 16, 2012
The Food and Drug Administration (FDA) is announcing a public Workshop on "Device Improvements for Pediatric X-ray Imaging." The main purpose of the workshop is to discuss the draft guidance "Pediatric Information for X-ray Imaging Device Premarket Notifications." This guidance will apply to x-ray computed tomography, general and dental radiography, and diagnostic and interventional fluoroscopy devices. The guidance document was released in draft form for public comment on May 10, 2012. A Notice was published in the Federal Register on this same date for an open comment period for the guidance document that runs through September 6, 2012. In addition to soliciting public feedback on the draft guidance, the FDA has organized this meeting to help identify issues relevant to radiation safety in pediatric x-ray imaging that may benefit from standards development or further research.
- Date, Time and Location
- Federal Register Notice [Not Yet Available]
- Public Comment
- Contact Us
This meeting will be held July 16, 2012. Registration will begin at 7:00am and the meeting will begin promptly at 8:00am at the following location:
FDA White Oak Campus (Building 31, Great Room)
10903 New Hampshire Avenue
Silver Spring , MD 20993
This meeting will also be webcast. Persons interested in viewing the webcast must register online by July 9, 2012. Early registration is recommended because webcast connections are limited. Organizations are requested to register all participants, but to view using one connection per location. Webcast participants will be sent technical system requirements after registration and will be sent connection access information after July 12, 2012. If you have never attended a Connect Pro event before, test your connection. Also available is a quick overview of the Connect Pro program. (FDA has verified the Web site addresses in this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.)
Federal Register Notice
The Food and Drug Administration is announcing a public meeting to discuss the draft guidance "Pediatric Information for X-ray Imaging Device Premarket Notifications."
- Federal Register Notice [Not Yet Available]
The draft guidance and other pediatric dose reduction efforts are part of FDA's Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging. More information can be found here:
- Press Release: FDA proposal aims to help reduce unnecessary radiation exposure for pediatric patients
- Draft Guidance: Pediatric Information for X-ray Imaging Device Premarket Notifications
- Notification of Availability of draft guidance [Not Yet Available]
- Pediatric X-ray Imaging Webpage: Provides information on the benefits and risks of imaging using ionizing radiation, recommendations for parents and health care providers to help reduce exposure to unnecessary radiation, and information for manufacturers of x-ray imaging devices.
- Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging
|Time||Subject||Name of Speaker|
|8:00-8:15||Structure of the Day and Logistics||Sean Boyd/Moderator|
|8:15-9:30||Session 1: Introduction|
|8:15-8:35||FDA's Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging||Sean Boyd|
|8:35-9:00||Pediatric dose reduction efforts||Thalia Mills|
|9:00-9:30||FDA's regulation of x-ray imaging devices||Mary Pastel|
|9:45-10:45||Session 2: Radiologic technologist's perspective||TBD|
|9:45-10:05||Perspectives from Pediatric X-ray Imaging Users|
|10:55-11:55||Session 3: Industry perspective||TBD|
|1:00-1:05||Afternoon session: introduction||Sean Boyd (moderator)|
|1:05-3:00||Open public comment|
|3:15-4:45||Roundtable discussion (includes Q+A from audience)|
|4:45-5:00||Closing remarks and adjournment||Sean Boyd|
As soon as a transcript is available, it will be accessible at: http://www.regulations.gov.
Regardless of attendance at the public meeting, any person may submit written or electronic comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852 http://www.regulations.gov. It is only necessary to send one set of comments. Comments are to be identified with the docket number FDA-2012-N-0385. Received comments may be seen in the Division of Dockets Management between 9am and 4pm, Monday through Friday. To ensure consideration, all comments must be received by September 6, 2012.
If you wish to attend this Workshop, you must register by 5 p.m. EST on July 9, 2012. If you wish to request to speak in the open session or to participate in the roundtable, you must register by 5 p.m. on June 25, 2012.
There is no fee to register for the Workshop and registration will be on a first-come, first-served basis. Early registration is recommended because seating is limited.
All meeting participants will be able to listen to all the presentations and roundtable discussion, as well as submit questions for the roundtable during the meeting.
Requests for Oral Presentations: This workshop includes a public comment session. If you wish to make an oral presentation during the open comment session, you must indicate this at the time of registration. You will be requested to indicate the topic(s) of your presentation. FDA requests that presentations focus on questions posed in the FR notice for the public meeting or any other comments on the draft guidance. FDA will do its best to accommodate requests to speak. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the public comment session. Following the close of registration, FDA will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants. Speakers will receive instructions on how to submit visuals, which must be submitted to FDA by July 9, 2012.
Requests to Participate in Roundtable Discussion: This workshop also includes a roundtable discussion. If you wish to participate in the roundtable discussion, you must indicate this at the time of registration. The number of roundtable participants will be limited, but all meeting participants will have the opportunity to view and submit questions to the roundtable. A request to be a participant does not guarantee a place in the roundtable discussion. Participants will be chosen to represent a broad variety of interest groups.
If you need special accommodations due to a disability, or additional information regarding registration, please contact Cindy Garris, Office of Communication, Education, and Radiation Programs, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg. 66, Silver Spring, MD 20993, phone: 301-796-5861, email: email@example.com.